Kyverna Therapeutics Inc (KYTX)

nice write up on SA
Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis
Apr 22, 2026, 3:31 PM ETKyverna Therapeutics, Inc. (KYTX) StockQURE

Terry Chrisomalis

Summary
• Kyverna Therapeutics maintains a "Strong Buy" rating, driven by positive clinical data and upcoming regulatory milestones for miv-cel.
• Miv-cel achieved statistically significant endpoints in SPS and demonstrated deep, durable responses in gMG, with 100% of patients off chronic immunosuppression at 24 weeks.
• A BLA filing for SPS is expected in 1H 2026, with additional data from gMG, RA, and PMS programs anticipated as expansion catalysts.
• The company is well-capitalized with $279.3M in cash, funding operations into 2028, and is positioned to leverage miv-cel as a pipeline-in-a-product across B-cell-mediated autoimmune disorders.
• Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »
• Sitewide Sale 2026: Get 20% Off

quantic69/iStock via Getty Images
The last time I spoke about Kyverna Therapeutics (KYTX), it was with a Seeking Alpha article entitled "Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing." With respect to this article, I mentioned that this company had achieved the primary endpoint of its single-arm registrational phase 2 KYSA-8 study using miv-cel for the treatment of patients with stiff person syndrome [SPS]. Specifically, this therapy allowed it to meet the primary endpoint of the change from baseline in the timed 25-foot walk [T25FW] at 16 weeks in a statistically significant manner. At that time, I had a "Strong Buy" rating on this stock because of this feat that was achieved.
It has also previously released positive data from its phase 2 portion of its phase 2/3 KYSA-6 registrational study using miv-cel for the treatment of patients with Generalized Myasthenia Gravis [gMG]. This was an interim analysis of 6 patients with gMG who were given miv-cel. It was noted that 100% [6 out of 6] of patients who took this therapy were able to achieve clinically meaningful reductions in MG-ADL and QMG scores from baseline regardless of prior biologic experience. Today, I'm going to maintain a "Strong Buy" rating on this stock. There are several reasons why I believe such a rating should remain. The first of which is because the company just released a late-breaking oral presentation of data from the KYSA-8 trial.
The point is that the company is well equipped to file its Biologics License Application [BLA] of miv-cel for the treatment of patients with stiff person syndrome [SPS] in the 1st half of 2026. This sets the ability for its autologous CD-19 CAR T-cell therapy, miv-cel, to become the first treatment option for patients with SPS. The second reason is because the company also presented long-term data showing that miv-cel was able to achieve deepening of responses in the ongoing KYSA-6 trial out to 52 weeks. I will be going over this specific program below because of the newly updated data. The final reason is because of miv-cel's ability to achieve deep B-cell depletion and immune reset, it holds potential across other autoimmune disorders.
There are two investigator-initiated trials [IITs] exploring the use of this CAR-T cell therapy in the targeting of patients with progressive multiple sclerosis [PMS] and rheumatoid arthritis [RA]. Positive data has been released from both of these early-stage programs already. However, there is an expectation of additional data to be released from the phase 2 portion of the phase 1/2 IIT study using miv-cel in difficult-to-treat RA patients in 2026. With an expected BLA filing of miv-cel for the treatment of patients with SPS in the 1st half of 2026, plus continued deepening of response observed using the same autologous CD-19 CAR T-cell therapy treating patients with gMG, I believe that this stock should remain with a "Strong Buy" rating.
Deepening Of Responses In Myasthenia Gravis Bodes Well For Ongoing Registrational KYSA-6 Study
As I mentioned above, Kyverna Therapeutics is doing very well in terms of its clinical advancement of miv-cel for the treatment of patients with stiff person syndrome [SPS]. This is in terms of it being able to achieve the primary endpoint of its phase 2 registrational KYSA-8 study using this therapy to treat these patients. It was able to present primary analysis data as part of an oral late-breaking presentation at the 2026 American Academy of Neurology [AAN] meeting on April 21, 2026. The company is on track to submit a BLA filing of miv-cel to the FDA for the treatment of these SPS patients in the 1st half of 2026. This sets up a major inflection point for investors to keep an eye on. However, for the purpose of this article, I'm going to go over the other indication that Kyverna is going after with miv-cel, which is Generalized Myasthenia Gravis [gMG]. The use of this autologous CD19-targeting CAR T-cell therapy is being evaluated to target this specific B-cell-mediated autoimmune disorder in the ongoing phase 2/3 KYSA-6 trial. I will also be going over other additional expansion opportunities, because the beauty of miv-cel is the ability to go after other B-cell-mediated disorders. Before going over the newly released KYSA-6 trial data, plus any catalysts that investors should keep an eye on, I believe that it is first important to go over what Generalized Myasthenia Gravis is and what the possible market opportunity for the company could end up being.
Myasthenia Gravis [MG] is characterized as a chronic autoimmune neuromuscular disorder whereby there is an effect on the voluntary muscles of the patient's body. What makes this disorder devastating is that it just doesn't only affect one aspect of a person's body; it instead goes after a variety of items. Such items it goes after are:
• Weakness in the arms and legs
• Difficulty swallowing
• Droopy eyelids
• Breathing problems
• Being able to speak
What exactly causes all of these problems? Well, MG is caused because there is a breakdown of signaling between the nerves and muscles of the body. Furthermore, this breakdown is caused by autoantibodies that are specifically produced by B-cells. If this is the case, then how can a therapy like miv-cel help? The reason why is because this CAR T-cell therapy is able to specifically deplete B-cells in the person's body by targeting the surface protein of CD19. In turn, autoreactive B-cells no longer occur, and this immune reset results in no disruption of signaling between the nerves and muscles. In addition, it is important to mention that MG has another form. MG is considered to be the overall disease type, where there are milder symptoms that deal with the eye and/or throat only. The more widespread version of MG, known as Generalized Myasthenia Gravis [gMG] involves arms, legs, respiratory muscles, and other aspects. The main advantage for miv-cel is that it offers complete B-cell depletion, while other therapies, like mRNA CAR-T, antibodies, and T-cell engagers, do not. There are two main issues with current available therapies for gMG, which are [Kyverna Corporate Presentation March 2026, slide #30]:
• Few of them reaching minimal system expression [MSE] for a patient
• The need for ongoing chronic immunosuppressant therapy
As I will be showing below in the clinical data that the company released, the KYSA-6 registrational trial was able to get rid of chronic immunosuppressant therapy for 24-weeks after a single dose of miv-cel. There is definitely a market opportunity here for Kyverna Therapeutics. That's because the global Generalized Myasthenia Gravis market is expected to reach $11.9 billion by 2034. This is a very large market, and the key item to point out is that the SPS is just a stepping stone over to gMG, as they are both part of the company's neuroimmunology franchise [Kyverna Corporate Presentation March 2026, slide #9]. The SPS centers to be laid out, if miv-cel is given FDA approval for it, will allow the company to transition over to treating patients with gMG.
In order to see whether or not miv-cel would be adequate enough to help treat patients with gMG, the company is in the process of running the ongoing phase 2/3 KYSA-6 study. The thing is that the company had released interim data already from this particular study, and this was in 6 patients with a cut-off evaluation date of October 3, 2025. It was noted that 100% [6 out of 6] of patients given a single dose of 1×10^8 CAR+T cells miv-cel achieved clinically meaningful reductions of MG-ADL and QMG scores from baseline of -8.0 points and -7.7 points at 24 weeks. This also was the first instance in which it was noted that all of these patients during this period of time were able to forgo their treatments of:
• Nonsteroidal immunosuppressants
• High-dose steroids >10 mg
• FcRn inhibitors
• Complement inhibitors
This was the last time around; however, the company just presented new data from the phase 2 portion of the phase 2/3 KYSA-6 study using miv-cel to treat these patients with gMG. What makes this new data significant? Well, it did add one other patient for starters. Thus, with the data update, there were 7 patients who were evaluated for MG-ADL and QMG scores. Secondly, the main item to note is that deep B-cell depletion was able to result in deep responses for an extended period of time.
With a cut-off date of February 25, 2026, it was noted that 7 patients with moderate-to-severe gMG given a single dose of 1X10^8 CAR+T cells of miv-cel achieved mean reductions in MG-ADL and QMG scores of -8.5 points and -11.3 points at week 24, respectively. Plus, like last time, it was noted that all patients were free of chronic immunosuppressant therapy as well. What's highly important in the newly updated data are two things. First, the responses that were achieved were sustained out to 52 weeks. However, this was only established in the three evaluable patients who were followed-up for that period of time. The second of which involves biomarker data, which lends credibility to the deep response observed over the extended period of time of 52 weeks. What do I mean by this? Well, the mechanism of action [MOA] ended up working out as intended, because there was a complete immune reset observed. That is, the expansion of CAR T-cells achieved resulted in deep B-cell depletion for all the patients who were treated. Remember above? Where I state that a lot of patients don't end up achieving MSE? Well, this is what came into play with this data, where 57% of patients achieved MSE, which is defined as having an MG-ADL score of 0 or 1. This proves the therapy has the ability to help these patients in a superior manner compared to currently approved therapies for gMG, along with an excellent safety profile. Speaking of safety, the data revealed that there were no high-grade cytokine-release syndrome [CRS] or immune effector cell-associated neurotoxicity syndrome [ICANS] either.
The main thing to state is that the data achieved in the phase 2 portion of the KYSA-6 trial was highly ideal and also bodes well for the ongoing phase 3 study. This is important because the phase 3 study is evaluating miv-cel for the treatment of these gMG patients based on both co-primary endpoints of MG-ADL and QMG scores. This phase 2/3 study was amended in 2025 to be a registrational one, and the hope is that the final outcome can be replicated. That doesn't mean that there isn't another catalyst to consider in 2026, beyond that of the expected BLA filing of miv-cel for the treatment of patients with SPS, expected in the 1st half of 2026. The beauty of the MOA of deep B-cell depletion is that it can be applied to a variety of other autoimmune disorders. One such program would be the ongoing phase 1/2 IIT evaluating the use of this autologous CD19-targeting CAR T-cell therapy for difficult-to-treat RA patients who have failed with multiple prior therapies. The point here is that the company is expected to release data from the phase 2 portion of this trial in 2026. Prior phase 1 data pointed to 4 out of 6 patients achieving an ACR20 response [20% improvement criteria], with 2 of these responders achieving ACR50. The point here is that these are difficult-to-treat patients because they have treatment-resistant RA. Lastly, other milestones would be data readouts of miv-cel-treated patients with lupus nephritis [LN] and progressive multiple sclerosis [PMS].
Financials
According to the 10-K SEC filing, Kyverna Therapeutics had cash, cash equivalents, and marketable securities of $279.3 million as of December 31, 2025. The reason for the cash on hand is because the company had enacted a public offering back on December 17, 2025, for a total of $100 million for starters. Not only that, but the company also had to obtain funding with respect to a Loan and Security Agreement with Oxford Finance LLC for an aggregate of $150 million. The way this loan is structured is as follows:
• One tranche of $40 million initially
• Two tranches of $30 million [total $60 million]
• Fourth tranche of $50 million
However, on November 3, 2025, it only drew $25 million from the first tranche under this loan agreement. The company is in excellent shape in terms of its cash on hand. Why do I state that? That's because in its Q4 and full-year 202 financial results update, it mentions that it believes its cash on hand is enough to fund its operations into 2028. The company burns about $39.3 million of cash per quarter. This is broken down into $30 million for its R&D expenses and then $9.3 million for its G&A expenses.
Risks to Business
There are several risks that investors should be aware of before investing in Kyverna Therapeutics. The first risk to consider would be in terms of the expected BLA filing of miv-cel for the treatment of patients with SPS. The risk here is there is no assurance that the FDA is going to accept the BLA of this CAR T-cell therapy for review of this neuroimmunology indication. Even if the FDA does accept the review of this drug, there can be no guarantee that U.S. marketing approval of it will happen. Especially in light of what has been going on with the FDA lately. There is a problem when it comes to obtaining approval on single-arm, open-label studies. Thus, because the KYSA-8 trial was not done in a randomized trial, this might potentially become an issue. For example, there was hope that uniQure (QURE) would be able to obtain FDA approval of its gene therapy AMT-130 for the treatment of patients with Huntington's Disease based on a single-arm study being compared to an external control. However, the FDA rejected it. Not only that, but meeting minutes from an FDA Type A meeting noted that the company must run a randomized, double-blind, sham surgery-controlled study. The point is that this presents itself as a risk because there is no assurance that it will be able to obtain U.S. marketing approval of miv-cel for the treatment of patients with SPS based on a single-arm, open-label trial.
The second risk to consider would be that of the other indication that miv-cel is being evaluated for, which is the treatment of patients with gMG in the ongoing phase 2/3 KYSA-6 registrational trial. As I have noted above, in the latest updated data from the phase 2 portion of this study, patients who took miv-cel achieved mean reductions in MG-ADL and QMG scores of -8.5 points and -11.3 points at week 24, respectively. This bodes well for the ongoing phase 3 study, because it utilizes these same co-primary endpoints. The risk here is that there is no assurance that these endpoints are going to be met in the ongoing phase 3 portion of this phase 2/3 KSYA-6 registrational trial for starters. In essence, there is no guarantee that the data generated thus far in these 7 patients will be reproduced in a larger pool of patients.
The third and final risk to consider would be in terms of the expansion opportunities for Kyverna Therapeutics. The reason why is because the hope of the company is that miv-cel could become a "pipeline in a product," which is to be able to be applicable towards other B-cell-mediated autoimmune disorders. With that said, as I mentioned above, it is in the process of exploring this autologous CD19-targeting CAR T-cell therapy in two ongoing ITTs targeting patients with PMS and difficult-to-treat RA. There is an expectation of data updates from both of these trials to happen during 2026. The risk here is that even though miv-cel has been shown to work well in being able to treat patients with SPS and gMG, there is no assurance that it will be able to continue to deliver solid clinical data in both of these IITs.
Conclusion
Kyverna Therapeutics has done well to continue to develop the use of its autologous CD19-targeting CAR T-cell therapy miv-cel for the treatment of patients with SPS. As I have gone over above, it already has reported positive topline data from its phase 2 KYSA-8 trial using this therapy to treat patients with SPS. The beauty of this is that it sets up a BLA filing of miv-cel for the treatment of these patients in the 1st half of 2026.
This program and proof of concept [POC] of miv-cel to achieve complete B-cell depletion, along with an immune reset, is further bolstered by long-term [52-week] follow-up data from the phase 2 portion of the phase 2/3 KYSA-6 trial targeting patients with gMG. Based on the ability to file a BLA in the 1st half of 2026 for miv-cel for the treatment of patients with SPS, plus the ability to expand to other B-cell-mediated autoimmune disorders, like gMG, PMS, and RA, I believe that it is important to maintain a "Strong Buy" rating on this stock.